Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Change in Cash: 2013-2024

Historic Change in Cash for Zevra Therapeutics (ZVRA) over the last 12 years, with Dec 2024 value amounting to -$9.3 million.

  • Zevra Therapeutics' Change in Cash fell 54.48% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $400,000, marking a year-over-year decrease of 96.29%. This contributed to the annual value of -$9.3 million for FY2024, which is 58.67% up from last year.
  • Zevra Therapeutics' Change in Cash amounted to -$9.3 million in FY2024, which was up 58.67% from -$22.4 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Change in Cash registered a high of $108.0 million during FY2021, and its lowest value of -$46.9 million during FY2022.
  • Moreover, its 3-year median value for Change in Cash was -$22.4 million (2023), whereas its average is -$26.2 million.
  • Per our database at Business Quant, Zevra Therapeutics' Change in Cash surged by 13,983.96% in 2021 and then tumbled by 143.40% in 2022.
  • Over the past 5 years, Zevra Therapeutics' Change in Cash (Yearly) stood at $767,000 in 2020, then spiked by 13,983.96% to $108.0 million in 2021, then tumbled by 143.40% to -$46.9 million in 2022, then skyrocketed by 52.18% to -$22.4 million in 2023, then soared by 58.67% to -$9.3 million in 2024.